These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 27628323

  • 1. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P, Puthanakit T, Anugulruengkitt S, Jantarabenjakul W, Phasomsap C, Chumket S, Yoksan S, Pancharoen C.
    Vaccine; 2016 Oct 17; 34(44):5279-5283. PubMed ID: 27628323
    [Abstract] [Full Text] [Related]

  • 2. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS, Houillon G, Jang GC, Cha SH, Choi SH, Lee J, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Kim HS, Bang J, Naimi Z, Bosch-Castells V, Boaz M, Bouckenooghe A.
    Hum Vaccin Immunother; 2014 Oct 17; 10(9):2656-63. PubMed ID: 25483480
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS, Jang GC, Cha SH, Choi SH, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Bang J, Naimi Z, Bouckenooghe A, Bosch-Castells V, Houillon G.
    Pediatr Infect Dis J; 2016 Feb 17; 35(2):e60-4. PubMed ID: 26535878
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Pancharoen C, Boaz M, Bouckenooghe A, Feroldi E.
    Vaccine; 2016 Nov 04; 34(46):5664-5669. PubMed ID: 27686833
    [Abstract] [Full Text] [Related]

  • 5. Long-term immunogenicity of the SA14-14-2 Japanese encephalitis (JE) vaccine (CD.JEVAX®) booster following chimeric JE (IMOJEV®) vaccine priming in Thai children.
    Chotpitayasunondh T, Suntarattiwong P, Yoksan S.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2407663. PubMed ID: 39353860
    [Abstract] [Full Text] [Related]

  • 6. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
    Feroldi E, Pancharoen C, Kosalaraksa P, Chokephaibulkit K, Boaz M, Meric C, Hutagalung Y, Bouckenooghe A.
    Pediatr Infect Dis J; 2014 Jun 31; 33(6):643-9. PubMed ID: 24717964
    [Abstract] [Full Text] [Related]

  • 7. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW, Lee HJ, Park JY, Cho HK, Kim YJ, Kim KH, Kim NH, Hong YJ, Kim DH, Kim HM, Cha SH.
    Vaccine; 2018 Mar 07; 36(11):1398-1404. PubMed ID: 29429815
    [Abstract] [Full Text] [Related]

  • 8. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
    Chotpitayasunondh T, Sohn YM, Yoksan S, Min J, Ohrr H.
    J Med Assoc Thai; 2011 Aug 07; 94 Suppl 3():S195-203. PubMed ID: 22043776
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
    Wijesinghe PR, Abeysinghe MRN, Yoksan S, Yao Y, Zhou B, Zhang L, Fleming JA, Marfin AA, Victor JC.
    Vaccine; 2016 Nov 21; 34(48):5923-5928. PubMed ID: 27773472
    [Abstract] [Full Text] [Related]

  • 10. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
    Kosalaraksa P, Watanaveeradej V, Pancharoen C, Capeding MR, Feroldi E, Bouckenooghe A.
    Pediatr Infect Dis J; 2017 Apr 21; 36(4):e108-e113. PubMed ID: 28030526
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study.
    Vu TD, Nguyen QD, Tran HTA, Bosch-Castells V, Zocchetti C, Houillon G.
    Int J Infect Dis; 2018 Jan 21; 66():137-142. PubMed ID: 29081368
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P, Limkittikul K, Sirivichayakul C, Chokejindachai W, Hattasingh W, Pengsaa K, Surangsrirat S, Srisuwannaporn T, Kaewma B, Yoksan S, Jun G, Zhumu B.
    Hum Vaccin Immunother; 2018 Apr 03; 14(4):900-905. PubMed ID: 29227177
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children.
    Sricharoenchai S, Lapphra K, Chuenkitmongkol S, Phongsamart W, Bouckenooghe A, Wittawatmongkol O, Rungmaitree S, Chokephaibulkit K.
    Pediatr Infect Dis J; 2017 Feb 03; 36(2):e45-e47. PubMed ID: 27846060
    [Abstract] [Full Text] [Related]

  • 14. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
    Paulke-Korinek M, Kollaritsch H, Kundi M, Zwazl I, Seidl-Friedrich C, Jelinek T.
    Vaccine; 2015 Jul 09; 33(30):3600-4. PubMed ID: 26036947
    [Abstract] [Full Text] [Related]

  • 15. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.
    Feroldi E, Capeding MR, Boaz M, Gailhardou S, Meric C, Bouckenooghe A.
    Hum Vaccin Immunother; 2013 Apr 09; 9(4):889-97. PubMed ID: 23442823
    [Abstract] [Full Text] [Related]

  • 16. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P.
    J Infect Dis; 2003 Oct 15; 188(8):1213-30. PubMed ID: 14551893
    [Abstract] [Full Text] [Related]

  • 17. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
    Feroldi E, Pancharoen C, Kosalaraksa P, Watanaveeradej V, Phirangkul K, Capeding MR, Boaz M, Gailhardou S, Bouckenooghe A.
    Hum Vaccin Immunother; 2012 Jul 15; 8(7):929-37. PubMed ID: 22777096
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.
    Chokephaibulkit K, Houillon G, Feroldi E, Bouckenooghe A.
    Expert Rev Vaccines; 2016 Jul 15; 15(2):153-66. PubMed ID: 26588242
    [Abstract] [Full Text] [Related]

  • 19. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
    Bouckenooghe A, Bailleux F, Feroldi E.
    Hum Vaccin Immunother; 2019 Jul 15; 15(1):72-79. PubMed ID: 30230947
    [Abstract] [Full Text] [Related]

  • 20. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO, Askling HH, Yoksan S, Rombo L, Riutta J, Vene S, Lindquist L, Vapalahti O, Kantele A.
    Vaccine; 2013 Dec 17; 32(1):119-23. PubMed ID: 24176496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.